In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 211 to 220 of 404

TitleTypeExpected publication date
Mental health guidelinesNICE guidelineTBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance
MRI-guided focused ultrasound subthalamotomy for treating Parkinson'sInterventional procedures guidance
MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson'sInterventional procedures guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Technology appraisal guidance
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All